CABRI

Some families hear a diagnosis and then hear something even harder: “There isn't much research.”

That’s the gap CABRI was created to help address.

CABRI supports scientific and therapeutic advances for rare diseases, orphan conditions, and cancers with unmet medical needs. The work is focused, patient-centered, and grounded in the belief that rare conditions deserve serious research attention.

Learn about our efforts 👉 cabrimed.org

Rare does not mean small impact.

Approximately 1 in 10 individuals live with a rare disease. CABRI has also provided more than $276,000 in research grants for rare diseases.

When awareness is low, facts like these matter. They remind us that rare disease research is not a small need. It’s a real and urgent one for families waiting for more answers.

Share this post to help more people understand why rare disease research deserves attention.

Rare disease families shouldn't have to wait for attention before they get hope.

Since 2005, CABRI has focused on supporting people too often overlooked by traditional research and funding, including rare diseases and rare cancers.
That work only moves forward because people choose to care.

If this mission resonates with you, consider making a donation. Even a single gift helps push research forward and reminds patients and families that they are not forgotten.

Learn more or give here: cabrimed.org/donate/

This Sunday is more than a date on the calendar.

National Cancer Survivors Day will be observed on Sunday, June 7, and the whole month of June is dedicated to recognizing survivors and the work still needed to improve life after diagnosis.

At CABRI, supporting cancer research means honoring not just the science, but the people and families behind every diagnosis.

As we head into the weekend, tag a survivor, caregiver, clinician, or researcher you want to recognize 🤍

Some conditions are rare. No one facing them should feel overlooked.

June is National Cancer Survivors Month, a time to recognize the more than 18 million cancer survivors in the U.S. and the challenges that don't always end when treatment does.

At CABRI, research is always about people first.

From rare cancers to underserved conditions, our mission is to support scientific and therapeutic advancements for those with unmet medical needs, while also investing in the next generation through science, education, and outreach.

On June 7, communities will come together for National Cancer Survivors Day®, honoring resilience, progress, and the work still ahead.

Rare cancers and rare diseases deserve more visibility.

Share this post and learn about our efforts: cabrimed.org

👉 CABRI funds research at the exact stage where most ideas die.

That is what sets us apart. Most organizations focus on what's already validated, while Cabri invests in what isn't.

There are ideas out there that could change lives, but without support early on, they often never get the chance. Cabri focuses on that stage to help ensure those ideas do not disappear before they can become something more. Because every breakthrough starts with someone giving it a chance.

Every donation helps give those ideas a real chance to become something more. Be part of what starts it → cabrimed.org/donate

A major shift is happening in rare disease drug development.

The FDA is introducing a new approval pathway that allows therapies to move forward without large clinical trials, using smaller, highly targeted studies instead.

For many rare conditions, large trials have never been realistic. This change opens the door for more therapies to reach patients faster.

At CABRI, this is where our work matters most. We help teams navigate complex development paths with smarter trial design, efficient data strategies, and a focus on what is actually achievable.

As the process evolves, precision becomes everything.

Learn what this means for the future of rare disease therapies ➡️ https://www.healio.com/news/rheumatology/20260223/fda-provides-new-approval-process-for-rare-disease-therapies-without-large-clinical-trials

Most people do not realize how medical breakthroughs actually happen. CABRI collaborates with leading institutions like University of Michigan, Karolinska Institutet, Technische Universität Dresden, and Cayman Chemical to support early-stage research and advance discoveries in rare diseases and underserved areas of medicine.

These partnerships bring together funding, expertise, and research infrastructure.

That means:
👉 More opportunities to study complex conditions
👉 More data to support discoveries
👉 A stronger path toward potential treatments

This is how progress actually moves forward, and in rare disease research, it wouldn't happen without collaboration.

More people should understand this. Share if you believe collaboration drives real progress.

Learn more about our mission at cabrimed.org.

The biggest misconception in drug development is that if the science works, the treatment will follow.

In reality, there are over 10,000 rare diseases, yet less than 5% have an approved treatment. More than 300 million people are affected worldwide, but funding and research remain limited. As a result, promising therapies stall, studies never get off the ground, and potential breakthroughs never reach patients, not because the science failed, but because the system did.

CABRI exists to help change that by funding research, supporting early-stage development, and working to move critical discoveries forward in areas that are often overlooked. Because progress is not just about discovery. It's about making sure it actually goes somewhere.